Short-term benefits of tolvaptan in hospital treatment of heart failure
This article has no abstract so we have provided the first paragraph of the full text.
Arginine vasopressin levels are elevated in heart failure, contributing to fluid retention and, thereby, worse outcomes. The EVEREST trials assessed the use of tolvaptan, a selective vasopressin V2 receptor antagonist, in patients hospitalized for acute heart failure symptoms. Gheorghiade et al. report the outcomes of two identical short-term trials, which took place across 359 medical centers.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
